Karuna Mittal

PreludeDx (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index747citations71works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(27), Microtubule and mitosis dynamics(20), Breast Cancer Treatment Studies(19), Cancer-related Molecular Pathways(10), Cancer, Hypoxia, and Metabolism(9)

Publications71 total

Limitations in the Application of Clinicopathologic Factors Alone in Predicting Radiation Benefit for Women With Low-Risk Ductal Carcinoma In Situ After Breast Conserving Surgery: The Impact of a 7-Gene Biosignature Based on 10-Year Ipsilateral Breast Recurrence Rates
International Journal of Radiation Oncology*Biology*Physics·2025
Abstract P3-08-20: The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In Situ
Clinical Cancer Research·2025
Novel multi-omic biosignature for identification of early-stage invasive breast cancer patients who do and do not benefit from adjuvant radiation treatment after breast conservation surgery.
Journal of Clinical Oncology·2025
A Novel Comprehensive Multi-Omic Biosignature to Assess Recurrence Risk and Adjuvant Therapy Benefit in Early-Stage Hormone-Positive Invasive Breast Cancer Patients
International Journal of Radiation Oncology*Biology*Physics·2024
ASO Visual Abstract: The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study
Annals of Surgical Oncology·2024Open Access
The Clinical Utility of a 7-Gene Biosignature on Radiation Therapy Decision Making in Patients with Ductal Carcinoma In Situ Following Breast-Conserving Surgery: An Updated Analysis of the DCISionRT® PREDICT Study
Annals of Surgical Oncology·2024· 16 citedOpen Access
Abstract PO5-15-11: A Novel Biosignature to Predict Radiation Therapy Response in Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Surgery
Cancer Research·2024
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin
Communications Biology·2024· 6 citedOpen Access
A Biosignature Integrating Immune and Metabolic Signaling Axes to Assess Limited Radiation Therapy Response in Early-Stage Breast Cancer from a Low-Risk Cohort
International Journal of Radiation Oncology*Biology*Physics·2023Open Access
Impact on Radiation Therapy Recommendation and Treatment Modality for Patients with Ductal Carcinoma In Situ Using the 7Gene Biosignature: Analysis of the PREDICT Study
International Journal of Radiation Oncology*Biology*Physics·2023Open Access
Analytical validation of the 7-gene biosignature for prediction of recurrence risk and radiation therapy benefit for breast ductal carcinoma in situ
Frontiers in Oncology·2023· 11 citedOpen Access
Data from Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4
2023Open Access
Supplementary Figure from Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4
2023· 1 citedOpen Access
Supplementary Figure from Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4
2023Open Access
Data from Hypoxia Drives Centrosome Amplification in Cancer Cells via HIF1α-dependent Induction of Polo-Like Kinase 4
2023Open Access
Supplementary Data from A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma <i>In Situ</i>
2023Open Access
Data from A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma <i>In Situ</i>
2023Open Access
Data from A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma <i>In Situ</i>
2023Open Access
Supplementary Data from A Quantitative Centrosomal Amplification Score Predicts Local Recurrence of Ductal Carcinoma <i>In Situ</i>
2023Open Access
Abstract P4-02-02: Changes in treatment recommendation for patients with Ductal Carcinoma In Situ using a 7-gene predictive biosignature: Analysis of the PREDICT Study
Cancer Research·2023
page 1 of 4Next →

Frequent Co-authors

Ritu Aneja(38), Padmashree C.G. Rida(27), Emad A. Rakha(18), Michelle D. Reid(17), Meenakshi V. Gupta(15), Michael S. Toss(13), Da Hoon Choi(12), Sergey Klimov(12), Guilherme Cantuaria(12), Guanhao Wei(11), Emiel A. M. Janssen(11), Andrew R. Green(10), Vaishali Pannu(8), Jaspreet Kaur(8), Håvard Søiland(8), Pat W. Whitworth(8), Steven C. Shivers(8), Troy Bremer(8), Ian O. Ellis(7), Islam M. Miligy(7)